The biotech company also has a partnership with Sanofi (SNY) for the development, manufacture and commercialization of IgM antibody agonists against inflammation and immunology targets.

The firm’s product pipeline includes IGM-2323, which is a CD20 x CD3 bispecific IgM antibody designed to treat patients with B cell Non-Hodgkin's lymphoma and other B cell malignancies ...

To address this problem, antibody engineers introduced a serine ... but is likely to also apply for IgG2, IgG3, IgE and IgM. The evolutionary advantage of functional monovalency is also evident ...

2 The different types of immunoglobulins (IgG, IgM, IgY, etc.) may also impact cross-reactivity and multiplexing. For example, secondary antibodies that react with IgG (H+L) will react with epitopes ...

Under these changes, it will halt further development of imvotamab, an IgM-based CD20 X CD3 bispecific antibody T cell engager, and IGM-2644, an IgM-based CD38 X CD3 bispecific antibody T cell ...

The O-specific polysaccharide of Klebsiella pneumoniae in patients with bloodstream infections is immunogenic, and its closely related subtypes are cross-reactive.

In a report released yesterday, Brian Abrahams from RBC Capital maintained a Hold rating on IGM Biosciences (IGMS – Research Report), with a ...

In a report released today, Michael Ulz from Morgan Stanley maintained a Sell rating on IGM Biosciences (IGMS – Research Report), with a price ...